Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estradiol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 7/20 | 0.83 |
| ▸ | LMNA | P02545 | 7/20 | 0.83 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.83 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.83 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.83 |
| ▸ | MEN1 | O00255 | 3/20 | 0.83 |
| ▸ | TSHR | P16473 | 2/20 | 0.83 |
| ▸ | PGR | P06401 | 2/20 | 0.83 |
| ▸ | AR | P10275 | 2/20 | 0.83 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.83 |
| ▸ | MAPT | P10636 | 2/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | RECQL | P46063 | 2/20 | 0.83 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.83 |
| ▸ | SHBG | P04278 | 2/20 | 0.83 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.83 |
| ▸ | HTR2B | P41595 | 2/20 | 0.83 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.83 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estradiol SCHEMBL17419498 | 1.00 | ESR1 (0.83) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL1965908 | 0.93 | ESR1 (0.81) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL301392 | 0.92 | ESR1 (0.89) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL8092599 | 0.92 | ESR1 (0.89) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL3223253 | 0.92 | ESR1 (0.89) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL9273501 | 0.91 | ESR1 (0.87) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL5887626 | 0.91 | ESR1 (0.91) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL28211603 | 0.91 | ESR1 (0.95) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL24037697 | 0.91 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2KMT2A | |
| Estradiol SCHEMBL18258335 | 0.91 | ESR1 (1.00) | ESR1LMNAHSD17B10ESR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6794384-B1 | Hydroxylation activated drug release | DE MONTFORT UNIVERSITY (GB) | 2004-09-21 | — | — | US | disclosed |
| EP-1069915-B1 | HYDROXYLATION ACTIVATED DRUG RELEASE | UNIV MONTFORT (GB) | 2003-06-25 | — | — | EP | disclosed |
| US-20020037296-A1 | HYDROXYLATION ACTIVATED DRUG RELEASE | SPEAR THERAPEUTICS LIMITED (GB) | 2002-03-28 | — | — | US | disclosed |
| EP-1069915-A2 | HYDROXYLATION ACTIVATED DRUG RELEASE | DE MONTFORT UNIVERSITY (GB) | 2001-01-24 | — | — | EP | disclosed |
| WO-1999040944-A2 | HYDROXYLATION ACTIVATED DRUG RELEASE | DE MONTFORT UNIVERSITY (GB) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037296-A1 | HYDROXYLATION ACTIVATED DRUG RELEASE | CYP1A1, CYP1B1, CYP1A2 | ESR1 202/4885LMNA 4111/4885HSD17B10 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.